Review of 2022 American College of Rheumatology (ACR) guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: what’s new?
Glucocorticoids (GC) have been used in medicine since the middle of the twentieth century, including for the treatment of various systemic rheumatic diseases. However, long-term use of GC may be accompanied by the development of serious complications, one of which is secondary osteoporosis, leading...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2024-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Glucocorticoids (GC) have been used in medicine since the middle of the twentieth century, including for the treatment of various systemic rheumatic diseases. However, long-term use of GC may be accompanied by the development of serious complications, one of which is secondary osteoporosis, leading to low-energy fractures, which affects the quality of life of patients and may lead to an increased risk of death. This article presents an overview with a discussion of the new edition of the guideline of the American College of Rheumatology (ACR) 2022 for the prevention and treatment of glucocorticoid-induced osteoporosis in adult patients. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |